With stabilizing interest rates and increased FDA activity, three biotech companies stand out: Schrödinger combines AI-driven drug discovery with established software revenue ($256M in 2025); Sarepta generates nearly $2B in annual product revenue from gene therapy despite ongoing safety concerns around Elevidys; and NRX Pharmaceuticals, a specul...

NRx Pharmaceuticals reported Q1 2026 financial results showing a net loss of $1.4 million, improved from $5.5 million in Q1 2025. The company advanced its preservative-free ketamine ANDA toward FDA approval expected in Q3 2026, initiated commercial manufacturing, and received FDA clearance for a Phase 2b/3 trial of NRX-101 combined with robotic-a...

NRx Pharmaceuticals announced it will release its first quarter 2026 financial results on May 18, 2026, followed by a conference call. The clinical-stage biopharmaceutical company is developing NMDA platform-based therapeutics for CNS disorders, with NRX-100 (preservative-free intravenous ketamine) and NRX-101 (oral D-cycloserine/lurasidone) in d...

NRx Pharmaceuticals announced the appointment of Glenn Tyson as its first Chief Commercial Officer. Tyson brings 25 years of pharmaceutical industry experience and clinical background in mental health treatment. The appointment comes as NRx anticipates FDA approval of its preservative-free ketamine ANDA and prepares to submit a New Drug Applicati...

NRx Pharmaceuticals received FDA preliminary alignment on labeling for its preservative-free ketamine generic drug application, with only minor formatting changes required. The company expects final approval under GDUFA in Summer 2026. The product addresses ketamine supply shortages and is manufactured in the US, aligning with FDA's focus on re-s...